Free tool
FAERS Monitor: Inspra
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021437 or its brand name (Inspra, Eplerenone). Reports on generic versions are filed under their own applications.
Reports
13,077
Serious
11,339
87% of reports
Hospitalization
6,830
Death reported
1,274
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea1,162
- acute kidney injury984
- cardiac failure969
- hypotension896
- fatigue701
- dizziness688
- diarrhoea597
- drug interaction550
- oedema peripheral537
- drug ineffective524
- nausea516
- off label use502
- asthenia470
- atrial fibrillation440
- fall427
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 41 |
| 2005 | 56 |
| 2006 | 63 |
| 2007 | 72 |
| 2008 | 114 |
| 2009 | 128 |
| 2010 | 148 |
| 2011 | 263 |
| 2012 | 320 |
| 2013 | 272 |
| 2014 | 326 |
| 2015 | 456 |
| 2016 | 553 |
| 2017 | 626 |
| 2018 | 790 |
| 2019 | 1,000 |
| 2020 | 1,212 |
| 2021 | 1,240 |
| 2022 | 1,176 |
| 2023 | 1,045 |
| 2024 | 1,133 |
| 2025 | 1,111 |
| 2026 | 932 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,082 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cardiac failureSignal | 969 | 19.6 | 18.5 | 16,981 |
| acute kidney injurySignal | 984 | 10.4 | 9.8 | 8,360 |
| atrial fibrillationSignal | 440 | 7.3 | 6.7 | 2,384 |
| hypotensionSignal | 896 | 7.2 | 6.8 | 4,812 |
| oedema peripheralSignal | 537 | 7.1 | 6.5 | 2,819 |
| drug interactionSignal | 550 | 5.6 | 5.2 | 2,078 |
| dyspnoeaSignal | 1,162 | 3.3 | 3.1 | 1,915 |
| dizzinessSignal | 688 | 2.2 | 2.1 | 471 |
| fallSignal | 427 | 2.1 | 1.9 | 237 |
| astheniaSignal | 470 | 2.0 | 1.8 | 242 |
| diarrhoea | 597 | 1.5 | 1.4 | 98 |
| fatigue | 701 | 1.4 | 1.3 | 101 |
| nausea | 516 | 1.0 | 1.0 | 1 |
| off label use | 502 | 0.9 | 0.8 | 3 |
| drug ineffective | 524 | 0.6 | 0.6 | 113 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.